DARE
NASDAQDare Bioscience Inc.
News · 26 weeks66+57%
2026-03-012026-08-23
Mix3790d
- SEC Filings13(35%)
- Other11(30%)
- Insider10(27%)
- Earnings2(5%)
- Offering1(3%)
Latest news
25 items- PRDaré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect SegmentPresident & CEO, Sabrina Martucci Johnson, discusses the Company’s shift to commercial stage, upcoming revenue opportunities, Ovaprene’s positive interim Phase 3 results and what could drive value over the next 12–18 monthsAccess the segment here SAN DIEGO, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, participated in a Virtual Investor CEO Connect segment. As part of the segment, Ms. Johnson discussed the Company’s tr
- SECSEC Form D filed by Dare Bioscience Inc.D - Dare Bioscience, Inc. (0001401914) (Filer)
- SECSEC Form 253G2 filed by Dare Bioscience Inc.253G2 - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” ListSAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that its President and Chief Executive Officer, Sabrina Martucci Johnson, has been named to the Forbes 2026 "50 Over 50: Innovation" list, recognizing women who are making significant professional impact later in their careers. The recognition places Ms. Johnson among a distinguished group of innovators and entrepreneurs recognized by Forbes and underscores what Daré Bioscience believes is an increasingly important story for patients, the healthcare i
- SECDare Bioscience Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- SECSEC Form 424B5 filed by Dare Bioscience Inc.424B5 - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesSAN DIEGO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that it has entered into a definitive securities purchase agreement with institutional investors for the purchase and sale of 4,379,581 shares of the Company’s common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof), at a price of $1.37 per share of common stock (or $1.3699 per pre-funded warrant) in a registered direct offering priced at-the-market under Nasdaq rules. Each pre-funded warrant will be exercisable upon is
- SECSEC Form 10-Q filed by Dare Bioscience Inc.10-Q - Dare Bioscience, Inc. (0001401914) (Filer)
- SECDare Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy AdvancesCompany launches Flora Sync LF5™, the company's first directly commercialized product, began generating revenue in July DARE to PLAY™ Sildenafil Cream progressing toward national dispensing and initial revenue in the third quarter of 2026, with prescriptions and preorders already being accepted Building a commercial ecosystem to make it easier for women to discover, access and purchase products specifically designed for women Clinical pipeline continues to advance, led by positive interim Phase 3 Ovaprene® results and initiation of the DARE-HPV Phase 2 study Company to host conference call and webcast today, August 13, 2026, at 4:30 p.m. Eastern Time – Access the webcast here SAN DIEGO,
- PRDaré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it will host a corporate update conference call and webcast at 4:30 PM Eastern Time on Thursday, August 13, 2026, to review its financial results for the quarter ended June 30, 2026 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 3808585. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors se
- PRDaré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRxA featured menopause telehealth option is now available to women exploring DARE to PLAY™, advancing Daré’s strategy to build a trusted women’s health ecosystem spanning products, education and access to care Collaboration will expand Daré’s commercial reach, strengthen consumer engagement and create a foundation for additional strategic relationships across women’s health SAN DIEGO, July 28, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the launch of a strategic collaboration with MyMenopauseRx, a specialized teleh
- SECDare Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth OpportunitiesSAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced the launch of its "Across the U.S." Virtual Bus Tour Webinar Series, a multi-event investor engagement initiative designed to provide shareholders with direct access to the Company's leadership and the opportunity to learn more about Daré's commercial strategy, product portfolio, growth opportunities and long-term vision. Hosted by President and Chief Executive Officer, Sabrina Martucci Johnson, the live webinar series will feature corporate presentat
- SECSEC Form 253G2 filed by Dare Bioscience Inc.253G2 - Dare Bioscience, Inc. (0001401914) (Filer)
- SECDare Bioscience Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- SECDare Bioscience Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Dare Bioscience, Inc. (0001401914) (Filer)
- PRDaré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell EventLive video webcast on Tuesday, July 14th, at 4:00 PM ETRegister here SAN DIEGO, July 09, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it will participate in a Virtual Investor Closing Bell event on Tuesday, July 14, 2026, at 4:00 PM ET. For the segment, Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, will provide a brief corporate overview highlighting the recent launch of FloraSync LF5™, the Company's strategy for thoughtfully building its commercial business while adv
- INSIDERDirector Matz Gregory W was granted 30,805 shares, increasing direct ownership by 73,345% to 30,847 units (SEC Form 4)4 - Dare Bioscience, Inc. (0001401914) (Issuer)
- INSIDERDirector Kelley Susan L. was granted 23,696 shares (SEC Form 4)4 - Dare Bioscience, Inc. (0001401914) (Issuer)
- INSIDERDirector Grossman Jessica D. was granted 26,066 shares (SEC Form 4)4 - Dare Bioscience, Inc. (0001401914) (Issuer)
- INSIDERDirector Rastetter William H was granted 38,862 shares, increasing direct ownership by 4,524% to 39,721 units (SEC Form 4)4 - Dare Bioscience, Inc. (0001401914) (Issuer)
- INSIDERDirector Steele Robin Joan was granted 26,540 shares, increasing direct ownership by 129% to 47,055 units (SEC Form 4)4 - Dare Bioscience, Inc. (0001401914) (Issuer)
- PRDaré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer PlatformSAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that Flora Sync LF5™, a vaginal probiotic capsule formulated specifically to restore microbiome balance and support lasting vaginal comfort, is now available for order. Flora Sync LF5 sales will mark the Company’s first direct consumer product revenue, representing Daré Bioscience’s transition from a pure development-stage biotech to a women’s health company with a revenue-generating product. Flora Sync LF5 is available exclusively through the DARE Hea
- PRDaré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” SegmentFirst consumer health product positions Daré for revenue generation while expanding its women's health leadership platform Access the segment here SAN DIEGO, June 25, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it participated in a Virtual Investor "What This Means" segment highlighting the company’s recent news announcing the upcoming June 2026 commercial launch of Flora Sync LF5™, a vaginal probiotic capsule formulated specifically to restore microbiome balance and support lasting vaginal comfort. For the
DARE FAQ
7 questionsWhat does Dare Bioscience Inc. do?
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil...Where does DARE stock trade?
Dare Bioscience Inc. (DARE) is listed on NASDAQ.What sector and industry is DARE in?
Dare Bioscience Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Dare Bioscience Inc. go public?
Dare Bioscience Inc. (DARE) completed its IPO in 2014.What are analysts saying about DARE?
Dare Bioscience Inc. has had 1 recent analyst action on file. The most recent action was from Roth Capital: Buy with a $1100.00 price target on 2021-06-30. Recent price targets cluster around $1100.00.What companies are similar to DARE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare DARE side-by-side with any of them on Quantisnow.How can I track DARE on Quantisnow?
Quantisnow aggregates Dare Bioscience Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DARE to receive live email and push alerts on every new disclosure.